Roundup, week 5 2024
Here is a collection of articles worthy of your time. Delivered every Sunday, to your inbox.
Neonatal Outcomes After COVID-19 Vaccination in Pregnancy
JAMA
This study, involving nearly 200,000 newborns in Sweden and Norway, finds that receiving the COVID-19 vaccine during pregnancy does not pose any risks to infants. Instead, it appears to be protective against severe complications in infants. Since the vaccine does not cross the placenta and cannot be found in umbilical cord blood, further study is needed to determine the cause of this protection.
Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China
Expert Review of Anti-infective Therapy
More evidence of the effectiveness of Paxolivid in the treatment of COVID-19.
Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy
Clinical Infectious Diseases
This small study showed a cumulative incidence of CMV reactivation of 27% after CAR T-cell therapy. No patient developed CMV end organ disease which raises the question: How much does cytomegalovirus viremia matter after chimeric antigen receptor T-cell therapy?
In other news
The fight over AI biosecurity risk takes a twist
Politico
Last week, OpenAI published a white paper downplaying the risks of ChatGPT being used for the creation of bioweapons. This Politico article summarizes some of the criticisms.